WebOct 28, 2024 · Sanofi has been working on this IL-2 candidate since 2024 when it acquired San Diego-based Synthorx for a value of $2.5 billion. The deal gave Sanofi control over … WebJul 1, 2024 · Abstract. THOR-707 (SAR444245) is a recombinant human IL-2 molecule that includes a PEG moiety irreversibly bound to a novel amino acid via click chemistry to …
Industry
WebBackground SAR444245 (THOR-707) is a recombinant human IL-2 molecule that includes a PEG moiety irreversibly bound to a novel amino acid via click chemistry to block the alpha … WebOct 29, 2024 · THOR-707 is currently being evaluated by Sanofi in an ongoing Phase 1 open-label, multi-center, dose escalation and expansion trial. This study is designed to evaluate … hugo boss aftershave black bottle
A Study of SAR444245 Combined With Cemiplimab for the …
WebApr 12, 2024 · The first clinical data underlying Synthorx's program, THOR-707, were disclosed at AACR. But the results leave some doubts. Three of 45 patients with advanced, metastatic solid tumors partially responded to treatment in testing. None had a complete response, while two also received Keytruda, making the benefit THOR-707 harder to … WebAug 9, 2024 · As THOR-707 is a “not alpha” IL-2, we compared the capacity of THOR-707 and rhIL-2 for induction of plasma IL-5, a key mediator of eosinophil activation, shown by … WebApr 10, 2024 · This follows its moves on Kymab, Kiadis, Principia and Synthorx, the last done to access the next-generation IL-2 project Thor-707, which at the time had not yielded any clinical date. Cytokines are a major focus of this year’s AACR, and presentation of Thor-707’s Hammer study just about showed hints of efficacy. hugo boss aftershave just different